Niclosamide extends health span and reduces frailty by ameliorating mTORC1 hyperactivation in aging models.

Pyeong Geun Choi, Hee Soo Kim, So-Hyun Park, Hyo-Deok Seo, Jeong-Hoon Hahm, Yang Hoon Huh, Tae-Il Jeon, Jiyun Ahn, Chang Hwa Jung

Aging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea; Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Republic of Korea. · pubmed

Paper

Abstract

Frailty is characterized by an increased vulnerability to disease and physical debilitation due to a decline in the body's capacity to maintain homeostasis during aging. Therefore, effective management of frailty is crucial for promoting health. Although the role of niclosamide (NIC), an autophagy promoter, has been studied for the treatment of cancer, infectious diseases, and metabolic disorders, no research has focused on its effects on aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Niclosamide extends health span and reduces frailty by ameliorating mTORC1 hyperactivation in aging models. The paper is relevant as it investigates a potential intervention targeting the underlying mechanisms of aging, specifically mTORC1 hyperactivation, which is associated with age-related decline and frailty.

Author of this paper? Send a correction.